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BACKGROUND
The expression, function, and modulation of the multidrug resistance (MDR) transporter gene ABCB1 is one of the most extensively studied mechanisms of drug resistance in human cancers (1) (2) (3) (4) (5) . The role of P-glycoprotein (P-gp) is well established in hepatic drug excretion, limitation of gastrointestinal absorption of substrate drugs, and as a key component of the bloodbrain, blood-testicular, and blood-placental barriers (3, (6) (7) (8) (9) . ABCB1 transfection and its inhibition by gene knockouts, RNA silencing and small molecule transport inhibitors have proven its function as a determinant of resistance to various anticancer drugs, including anthracyclines, taxanes, vinca alkaloids, and others, including a large fraction of new drugs in development (1, 8, 9) . Among many clinical trials with various inhibitors of P-gp in attempts to reverse drug resistance, the large majority have been negative, and only a few show some evidence of clinical benefit (2) .
Despite the significant advances in understanding the functional aspects of P-gp, however, the regulation of the ABCB1 gene and its impacts on clinical trials are not well-elucidated. In this review, we mainly focus on our recent understanding of genetic and epigenetic aspects of ABCB1 expression, and their cooperation with transcription factors (TFs) on the ABCB1 gene.
We shed light on how molecular signaling coordinated with epigenetic mechanisms controls ABCB1 expression. These regulatory insights derived form the ABCB1 model may also be useful for deciphering non-ABCB1-mediated drug resistance and for prevention and molecular intervention of MDR in clinic.
REGULATION OF THE ABCB1 GENE

Genomic instability and ABCB1 activation
Mechanisms underlying the intrinsic genomic instability of cancers have been an important area of research. Using Luria-Delbruck fluctuation analysis in the human uterine sarcoma cell line MES-SA, we showed that spontaneous mutational events underlie acquired MDR in these cells, and activation of ABCB1 is a frequent mechanism for cellular resistance to doxorubicin, paclitaxel, and vinblastine (10-13), but not to etoposide (14) . Structurally, Fojo and co-workers proposed that gene rearrangements serve as an important mechanism to control ABCB1 expression in many cases by juxtaposition of the native ABCB1 promoter to transcriptionally
Research. Regulation of the ABCB1 Gene 4 active promoters of many unrelated genes (15) . This mechanism was also found in some cancer patient samples from both leukemias and lymphomas, suggesting its potential clinical importance (16) . Several oncogenes including Ras, c-Raf, and c-Raf kinase have been implicated in ABCB1 regulation (17) (18) (19) . These studies suggest that oncogenes play a role in regulating the expression of ABCB1, possibly via malignant transformation processes.
During cellular transformation and tumor progression, one of the most commonly observed alterations is mutation in the TP53 tumor suppressor gene. There is substantial evidence that p53 is involved in regulation of ABCB1. The general observation is that the wild-type p53 represses and mutant p53s enhance ABCB1 promoter activity (5, 17, 20, 21) . Moreover, the interacting site of p53 on the ABCB1 promoter has been identified (22) . Hence, alterations or interactions in the p53 system have linked MDR to the p53-mediated signal pathway. Suppression of MDM2, a potent inhibitor of p53, by Nutlin-3 inhibits the functions of P-gp and ABCC1 (MRP1) in drugresistant neuroblastoma and rhabdomyosarcoma cell lines (23) . These studies suggest that the p53 system is involved in the regulation of ABCB1, possibly by direct interaction with the ABCB1 promoter. Thus, restoration or mimicry of wild-type p53 function may be a strategy to reduce or prevent MDR and sensitize cancer cells to anticancer drugs.
Epigenetic mechanisms that control ABCB1 expression
ABCB1 expression was also shown to be associated with demethylation of the ABCB1 promoter in the promyelotic leukemia (PML) cell line HL-60 after drug selection (24) , human Tcell leukemia cells treated with the demethylating agent 5'-azadeoxycytidine (25) , AML clinical samples (26) , adult acute lymphocytic leukemias (ALLs) (27) , and bladder cancers (28) . These data suggest that demethylation of the ABCB1 promoter activates ABCB1 expression in cancer cell lines and also in clinical cancer patients.
Jin and Scotto further showed that both histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate ABCB1 mRNA levels in SW620 (human colon carcinoma) cells when the cells were transiently treated with the HDAC inhibitor (HDACi) trichostatin A (TSA) (29) . We have demonstrated that a 20-fold increase in acetylated H3 (acetyl-H3) in the nucleosomes within the 968-bp region of the MDR1 far upstream promoter (P2), but not within the native ABCB1 promoter (P1), in doxorubicin single-step selected mutants of MES-SA cells (13) . Reciprocally, a 35-fold increase in acetyl-H3 was found in the ABCB1 P1, but not in the P2
Research. Regulation of the ABCB1 Gene 5 promoter, in step-wise selected MES-SA/Dx5 cells (13) . The detailed molecular events that are responsible for this differential utilization of the ABCB1 promoters are unclear. However, this is the first epigenetic evidence demonstrating that different cytotoxic regimens could result in distinct routes that lead to differential ABCB1 activation. The importance of acetyl-H3 in the regulation of ABCB1 was also confirmed by an independent study, in which Baker et al.
demonstrated that upregulation of ABCB1 by anticancer drugs was associated with a dramatically induced acetyl-H3, but not acetyl-H4, on the MDR1 P1 promoter in CEM-Bcl2 and in SW620 cells by 24-hour drug induction (30) . Similarly, a repressive histone marker, trimethylated H3-Lys9 was found to be associated with the expression of another multidrug transporter ABCG2 (31) . These studies indicate that the acetylation status of H3 plays an important role in the regulation of some ABC transporters.
Transcriptional regulation of the MDR1 promoter
A wide-ranging evaluation of the roles of TFs in the regulation of ABCB1 was provided by Regulation of the ABCB1 Gene 6 complex represents a positive or negative regulator for the chromatin-embedded MDR1 gene was not determined in MCF-7 cells in the previous study (32) . The association of the SWI/SNF complex (containing hBrm) on the ABCB1 promoter was confirmed by El-Osta and Colleagues (35) . In their study, hBrm appears to be complexed with the methyl-CpG binding protein (MeCP2) to repress the endogenous ABCB1 promoter in CEM-CCRF cells. In general, we believe that the regulation of ABCB1 expression either by C/EBPβ or hBrm alone or by the C/EBPβ-hBrm complex is both cellular-context and chromatin-status dependent. The regulatory complex may be controlled indirectly by autocrine production of interleukin 6 (IL-6), which was shown to associate with ABCB1 activation via a C/EBPβ pathway in breast cancer cells (36) .
Cooperation among epigenetic components, TFs, and chromatin-remodeling factors
The interactions among DNA methylation, histone modification, chromosomal remodeling, and TF positioning are highly regulated in order to achieve a desired phenotype. In the case of ABCB1, a hypermethylated promoter with deacetylated H3 represents a doubly repressive status of the ABCB1 promoter, that needs to be released prior to achieving ABCB1 expression. Indeed, in P-gp negative MES-SA and MCF-7 cells, the ABCB1 chromatin was deacetylated (13, 37) .
The occupancy of both MeCP2 and the corepressor MBD2 would reinforce the repressive status of the ABCB1 chromatin (37). Hence, release of both MeCP2 and HDAC1 from the methylated ABCB1 promoter modulates ABCB1 expression (38) . Such a derepression mechanism facilitates acetylation of a preferred histone species (e.g., H3) at a specific residue (e.g., Lys9), thus enabling the opening of compact chromatin and positioning of general TFs as well as RNA polymerase II at the ABCB1 promoter (Figure 1 ).
The Y-box of the ABCB1 promoter is likely a central docking site to recruit TFs such as p300/CREB binding protein-associated factor (p/CAF), that has HAT activity, and to recruit C/EBPβ that has chromatin-remodeling ability (29, 32) . HAT complexes were shown to stabilize the SWI/SNF complex binding to promoter nucleosomes with specificity (39) . Thus, these studies illustrate a structural and functional link among the Y-box, Y-box binding proteins, C/EBPβ, HATs, HADCs, MeCP2, and the SWI/SNF complex on the ABCB1 promoter. They also suggest a complex interaction pattern that is crucial for the initiation of a cluster of genes, including ABCB1 that contribute to the intractability of cancer cells to various therapies ( Figure   1 ). Y-box binding proteins thus represent important markers for MDR (40, 41 Regulation of the ABCB1 Gene 7 YB-1 also caused suppression of EGFR and HER-2/neu, reinforcing the putative association among the YB-1-Her2-ABCB1 network (Figure 1 ).
CLINICAL-TRANSLATIONAL ADVANCES
Clinical relevance of ABCB1
The clinical relevance of ABCB1 expression was predominantly focused on the ABCB1-encoded P-gp, which has been used as a therapeutic target to enhance chemotherapies by inhibiting the transporter function. However, the clinical significance of P-gp inhibition as a therapeutic strategy has proven to be quite difficult to establish. A major confounding issue in clinical trials of MDR modulation has been the altered pharmacokinetics of chemotherapeutic drugs such as doxorubicin, daunorubicin, etoposide, and taxanes, both as a result of P-gp inhibition and as a result of inhibition of other drug transporters and CYP 3A4 (6, (42) (43) (44) (45) (46) . In some cases, such as the use of the cyclosporine analogue valspodar (PSC-833) in AML, substantially increased toxicity was observed, resulting in an increased toxic death rate (47) .
The most positive data for MDR modulation was the SWOG 9126 trial using high dose cyclosporine infusion in relapsed and high risk AML (48) . However, other Phase III studies in AML using cyclosporine or valspodar have been negative (47, 49) . The discrepancies in results between these studies may be due to different patient populations, with SWOG 9021 containing a large proportion of secondary AML expressing high levels of P-gp. Patient selection on the basis of screening for functional P-gp expression may be important. Baer et al. reported a trend towards benefit in a subset of AML patients with PSC-modulatable efflux, who had an increase from 5 to 14 month median survival when valspodar was added to induction chemotherapy (P = 0.07) (47) . Recently, a phase III trial of the potent and specific P-gp inhibitor zosuquidar was reported as negative in older patients with AML (50). In addition to studying an unselected AML population, the schedule of zosuquidar in this ECOG study was suboptimal, given the short half life of the drug (51, 52) .
Incomplete inhibition and alternative MDR mechanisms in clinical trials
Incomplete P-gp inhibition, drug interactions leading to excessive toxicities, and suboptimal clinical trials designs are all reasons for the lack of success of P-gp inhibition as a therapeutic approach. However, the most significant obstacle may be the expression of multiple, redundant Co-expression or selection for other drug transporters as alternative MDR mechanisms has been reported in the setting of inhibition of P-gp function in AML. These other transporters include (54) (55) (56) (57) . Co-expression of P-gp and other transporters has also been reported in normal and leukemic stem cells (58, 59) . These data imply that the coexistence of P-gp with other transporters such as ABCG2 is a default stemcell program in AML, and perhaps in other cancers. Coexpression of ABCB1 and ABCG2 is obviously associated with the acetylation of histones, particularly H3 (13, 30, 31, 60) . Thus, the role of epigenetic-based therapies in drug resistance should be further investigated using HAT (rather than HDAC) inhibitors, targeting acetyl-H3.
ABCC1 (MRP1), ABCC2 (MRP2), and ABCG2 (BCRP/MXR)
Epigentic therapies and clinical MDR
The use of HDAC inhibitors in treating human cancer patients may result in expression of ABCB1 or ABCG2 or both. Thus, induction of ABCB1 expression by FK228, a depsipeptide that specifically inhibits class I HDACs, was reported in normal peripheral blood mononuclear cells and in circulating tumor cells, acute promyelocytic leukemia (APL) cells, and osteosarcoma (61) (62) (63) . Coadministration of all-trans retinoic acid (ATRA) with FK228 increased both acetyl-H4 and acetyl-H3-Lys9 at the ABCB1 promoter in acute APL cells (62) . Hence, upregulation of ABCB1 by HDAC inhibitors such as FK228 could reduce its antitumor efficacy through the classical MDR mechanisms.
Pathway intervention and prevention of MDR
Many survival signals that are associated with ABCB1 activation have been endogenously active in AML, including PI3K/Akt, Raf, and PKC. These factors can also contribute to ABC transporter-independent drug resistance mechanisms. Thus, coexistence of other non-ABCB1 resistance mechanisms in AMLs elucidates the limitations of P-gp inhibitors as a treatment strategy, and underlies the need both for a deeper understanding of the inter-relatedness of drug resistance mechanisms and for novel strategies to deal with resistance. Such strategies might include identification of shared regulators of multiple resistance pathways, and concurrent Regulation of the ABCB1 Gene 9 targeting of such pathways. Pharmacological reactivation of p53 in human cancer with a mutant p53 status is one such example. In murine tumor models, restoration of functional p53 induces a senescence program (in liver carcinomas and in sarcomas) and apoptosis (in lymphoma), which consequently leads to tumor clearance or regression (64, 65) . These genetic experiments in mice have proved the principle of p53-based therapy. Restoration of functional p53 might also increase therapeutic efficacy of some anticancer drugs through the suppression of ABCB1.
Acetylation of p53 results in destabilization of the p53-MDM2 interaction loop, thus activating p53-mediated stress response (66) . The SNP309 G/G genotype that influences MDM2 transcription levels is considered an independent risk factor in B-CLL (67) and is associated with poor survival among early-stage NSCLC patients with squamous cell histology (68) . Inhibitors that target MDM2-p53 interactions might also concomitantly target MDR mechanisms.
CONCLUSIONS
Multiple genetic and epigenetic regulatory mechanisms constitute a tightly coordinated network that determines predominant drug-resistant phenotypes including classical P-gp-related MDR. We elucidate the complexities of MDR in human malignancies. The role of P-gp expression in clinical drug resistance and drug disposition is well established, and transport by Pgp is an important consideration in the development of new anticancer drugs. However, P-gp targeting to sensitize cancers to therapies has not been successful in clinical trials. The negative clinical trials are linked to limited inhibition of P-gp, excess toxicities from inhibition of drug disposition, alternative MDR and other drug resistance mechanisms, and suboptimal clinical trial designs. Targeting the regulation of ABCB1 and related resistance mechanisms by new therapeutic approaches, including epigenetic modulators, will be subject to some of the same constraints as P-gp inhibitors. These include the complexity and redundancy of drug resistance mechanisms, effects on cytotoxic drug distribution and excretion, as well as the fundamental importance of these MDR mechanisms in stem cell biology and survival. 
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